EPC-003 / Elpis Biopharma - LARVOL DELTA

Safety and efficacy of B7H3/IL13Rα2 bispecific armored CAR-T for treatment of recurrent/refractory glioblastoma. (ASCO 2026) - P1 | "B7H3/IL13Rα2 bispecific CAR-T exhibits favorable safety in recurrent/refractory GBM: Low-dose, PK-guided multiple infusions avoided DLT, with all AEs reversible via standard interventions. It also demonstrates robust in vivo expansion and persistence, supporting subsequent dose-escalation trials. Clinical trial information: NCT07193628."

Bispecific • CAR T-Cell Therapy • Clinical • First-in-human • IO biomarker • Brain Cancer • Glioblastoma • Hematological Disorders • Solid Tumor • Thrombocytopenia • CD276 • IL13RA2 • MGMT

Development of human B7H3/IL13Ra2 bispecific armored CAR-T for treatment of glioblastoma. (ASCO 2026) - "EPC-003, a multi-mechanism armored bispecific CAR-T, demonstrated favorable preclinical safety, developability, robust anti-tumor activity, and potential durability. These data support its advancement into an investigator-initiated clinical trial for the treatment of glioblastoma."

Bispecific • CAR T-Cell Therapy • IO biomarker • Brain Cancer • Cerebral Hemorrhage • Glioblastoma • Solid Tumor • CD276 • IL13RA2 • IL2

Discovery and development of fully human IL13Ra2/B7H3 bispecific armored CAR-T for treatment of glioblastoma (AACR 2025) - "The multi-modular and multi-mechanism EPC-003 is a promising candidate that potentially enhances anti-tumor activity, prevents/treat target escape, and reduces immunosuppression within the TME. These novel mechanisms of EPC-003 could potentially translate into durable and enhanced clinical efficacy for GBM therapy."

Bispecific • CAR T-Cell Therapy • Late-breaking abstract • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • CD276 • IL13RA2 • IL2

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

First-in-human • New P1 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore (PRNewswire) - "Elpis Biopharmaceuticals...announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers....As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine....These technologies are already being investigated in Elpis' global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types."

Licensing / partnership • Colorectal Cancer • Ovarian Cancer • Pancreatic Cancer

Elpis Biopharmaceuticals to Present Two "Late-Breaking" Posters Detailing Its Pioneering CAR-T Cell Therapy Technologies at AACR Annual Meeting 2025 (PRNewswire) - "The first poster...details research involving EPC-002...As presented at AACR, EPC-002 demonstrated an ability to reduce regulatory T cell proliferation, modulate CAR-T and bystander immune cell activation, enhance TIL infiltration, overcome TME suppression, and mediate anti-tumor activity. These mechanisms were highlighted in preclinical mouse models in which EPC-002 enabled complete tumor regression and long-term persistence with very low dose of 0.3M CAR-T cells in tumor rechallenging studies....The second poster...describes the ongoing development of EPC-003....As presented at AACR, in an orthotopic GBM mouse model, EPC-003 induced tumor regression as early as day 6 following intracranial injection of 2 × 10⁶ CAR-T cells. Moreover, intravenous injected CAR-T cells successfully penetrated the BBB, achieving significant tumor regression by day 13 post-treatment."

Preclinical • Glioblastoma • Solid Tumor